Plain-English translation of NCT07400757 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether atorvastatin (a statin) and vitamin D supplements, added to your standard thyroid eye disease treatment, can help reduce inflammation and disease activity. Thyroid eye disease is an autoimmune condition that causes eye swelling, pain, and sometimes vision changes. Researchers want to see if these two medications—which have anti-inflammatory properties—can improve outcomes when used alongside standard care.
Current treatments for active thyroid eye disease often rely on steroids and immunosuppressive drugs, which can have serious side effects and don't work equally well for everyone. Recent research suggests that this medication and vitamin D may help reduce inflammation through different mechanisms, offering a safer add-on option to improve treatment outcomes.
You likely qualify if…
You likely don't qualify if…
You will receive standard thyroid eye disease treatment for 24 weeks (about 6 months). Depending on which group you're assigned to, you may also take a daily statin pill and/or a vitamin D supplement. The study uses a 2×2 design, meaning some participants get one medication, some get both, some get the other, and some get standard care alone. You'll visit the clinic regularly so researchers can track your eye symptoms, inflammation levels, and how well the treatment is working.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
Taiwan